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Abstract  
Cardiac tumours are uncommon in the canine and feline population and often an incidental finding. 
Common types include haemangiosarcoma (HSA), aortic body tumours (chemodectoma and 
paraganglioma) and lymphoma. These neoplasms can cause mild to severe, life-threatening clinical 
signs; they are independent of the histological type and may be related to altered cardiovascular 
function or local haemorrhage/effusion into the pericardial space.  
Cardiac tumours may require symptomatic treatment aimed at controlling tumour bleeding and 
potential arrhythmias, and other signs caused by the mass effect. Other treatment options include 
surgery, chemotherapy and radiotherapy. For all medical therapies, complete remission is unlikely 
and medical management, beyond adjunctive chemotherapy in HSA, requires further investigation 
but combination chemotherapy is recommended for lymphoma.  
The aim of this report is to summarize and critically appraise the current literature in a descriptive 
review. However, interpretation is limited by the lack of definitive diagnosis and retrospective 
nature of most studies. 	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Introduction 
 
Cardiac tumours are uncommon in the canine population. Several small studies report an incidence 
between 0.12%1 and 4.33%2, while a larger retrospective study3 reported 1,383 dogs with tumours 
of the heart from a total population of 729,265 dogs (0.19% incidence) in a veterinary medical 
database. These neoplasms occur most frequently in middle age to older dogs, with the exception of 
lymphoma, which may also affect younger patients.3  
The aim of this report is to summarize and critically appraise the current literature in a descriptive 
review. However, interpretation is limited by the lack of definitive diagnosis and retrospective 
nature of most studies.  
 
The most common type of cardiac tumour is haemangiosarcoma (HSA, 69%).3, 4 In addition to 
HSA, the following tumours are commonly reported: aortic body tumours (chemodectoma and 
paraganglioma)4, 5, lymphoma6 and ectopic thyroid carcinoma.3, 4, 7-9 Less frequently, several other 
types of tumours are documented: thyroid adenoma10, melanoma4, mast cell tumour4, blastoma4, 
granular cell tumour11, mesothelioma12-15, myxoma16-20, myxosarcoma21, 22, mesenchymoma23, 
undifferentiated sarcoma of presumptive myofibroblastic origin24, fibroma25, fibrosarcoma26-28, 
rhabdomyoma29, rhabdomyosarcoma30, leiomyoma31, leiomyosarcoma32, chondrosarcoma33, 34, 
osteosarcoma35-37, paraganglioma38, peripheral sheath nerve tumour39, hamartoma40 and lipoma.41-43 
Furthermore, single cases of valvular osteosarcoma44, valvular myxosarcoma45 and valvular 
metastasis of disseminated histiocytic sarcoma46 are described in the literature.   
 
Cardiac tumours can be either benign or malignant (and primary or secondary).7, 8 Reports 
regarding the rate of primary versus secondary tumours in canine patients are contradictory: when 
retrospectively reviewing a veterinary medical database, Ware and Hopper reported that most of the 
tumours identified in the canine heart were primary (84%) and only a 16% were thought to be 
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metastatic.3, 7 On the other hand, when Aupperle et al. reviewed necropsy findings with histological 
analysis, they reported cardiac tumours in 41% of the study population, and of these most were 
metastatic (69% metastases, 31% primary).7 In this study, metastases were found in the heart in 
36% of the dogs with malignant neoplastic disease, which is comparable to humans where cardiac 
metastases are more common than primary cardiac tumours.7, 47 The difference between the two 
veterinary studies likely reflects the different study populations: the Ware study3 cases were 
identified from a data base search for “cardiac tumours” and only two-thirds of the cases included 
had histological classification. Additionally, metastatic disease may have been coded in the 
database as the primary diagnosis, not as a cardiac tumour.  In the necropsy study47, clinically silent 
cardiac metastases are likely to have been identified, and in fact reports that cardiac metastases 
were not suspected based on clinical signs in any case.  
 
A study assessing location of cardiac neoplasms documents that most primary cardiac tumours are 
located in the right atrium/right atrial appendage (63%), followed by heart base (18%) and left 
ventricle (9%).7 However, the data are derived mainly from post-mortem evaluations, thus possibly 
reflecting a bias towards the more aggressive or malignant types of cardiac tumours, including those 
that cause pericardial effusion or more severe clinical signs and patient death. Most right 
atrial/auricular masses, likely HSA, show malignant tumour characteristics including the tendency 
to metastasize, regardless whether they occur with or without pericardial effusion. In contrast, heart 
base masses such as chemodectomas often display more benign behaviour, with a low incidence of 
metastasis and variable occurrence of pericardial effusion; indeed some dogs may be completely 
asymptomatic. Thus tumours of this type are likely to be underestimated by post mortem-based 
studies. Other heart base tumours reported include adenomas and adenocarcinomas, with adenomas 
most common: these would similarly tend to be under-represented in a necropsy study. 48, 49 
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Unlike primary tumours, most metastatic lesions reported by post-mortem (75%), are found in the 
inner third of the left ventricular free wall, in the interventricular septum, or both. Only 25% of 
metastatic tumours are found in the right atrium or right ventricular wall, or both.7, 50 
 
Ware et al. reported that the breeds with higher incidence of cardiac tumours are German Shepherd 
dogs (GSD), Golden Retrievers, Boxers, Bulldogs, Boston Terriers, Scottish terriers, English 
Setters, Afghan Hounds, Flat Coated retriever, Irish Water Spaniels, French Bulldogs and Salukis.3 
Breeds specifically recognised to be at increased risk of developing cardiac HSA (as well as splenic 
HSA) are GSD and Golden Retrievers.3, 4 Brachycephalic dogs are predisposed to aortic body 
tumours, in particular Boxers4; this was thought to be associated with chemoreceptors stimulation 
caused by chronic hypoxia51, 52, however this hypothesis has never been proven and instead a 
genetic component is more likely.51 Secondary cardiac tumours can affect any breed.  
 
 
Most common canine tumour types  
 
Haemangiosarcoma 
Haemangiosarcoma (HSA) is the most common cardiac tumour in dogs.3, 4 Diagnosis is often 
presumptive, and relies on imaging findings and anatomical location. HSA commonly presents as a 
mass involving the right atrium (Fig. 1C) and the right atrial appendage.3, 8 In the authors’ 
experience, HSA also infrequently presents as a diffuse infiltrative tumour (Fig.1D, Fig. 2B). Atrial 
HSA can present as a solitary tumour, or occur concurrently with a splenic mass.53, 54 The rate of 
concurrent right atrial masses in dogs that present to the veterinarian for investigations of splenic 
HSA varies between 8.7%53 and 25%54, therefore echocardiography may be indicated in these cases 
as part of the staging process. On the other hand, the rate of concurrent splenic HSA in dogs that 
present to the hospital for cardiac HSA has been reported as 29%. Interestingly, 42% of these dogs 
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had non-splenic metastases at presentation53: it is therefore unclear whether these patients have two 
primary tumours, or one primary and a metastatic lesion in the spleen. In addition, the risk for non-
splenic metastasis appears to decrease with age, but an age related reduction in the frequency of 
concurrent splenic and cardiac HSA is not documented.  
Diagnosis is very rarely attempted by means of biopsy and/or cytology, because of the perceived 
risks of non-representative sampling and significant complications. Surgery and adjuvant 
chemotherapy have been described in the management of atrial HSA, with adjuvant chemotherapy 
being considered the most effective treatment in these cases.  
 
Lymphoma  
Lymphoma involving the heart and surrounding structures is infrequently reported in dogs. 
“Primary” cardiac lymphoma is defined in human medicine as lymphoma affecting the heart, the 
pericardium or both.55 According to the WHO criteria for staging of lymphoma in dogs, cardiac 
lymphoma with pericardial effusion is classified as stage V (extranodal in an organ other than liver 
or spleen), substage b (with clinical signs). This stage of lymphoma may be subject to a worse 
prognosis overall, but there is no specific data for the cardiac form. The largest study on cardiac 
lymphoma evaluated outcome in 12 dogs, of which 5 were treated with multidrug chemotherapy.6 
In that report, cardiac lymphoma was diagnosed by means of cytology of the pericardial effusion in 
8 dogs; immunohistochemistry was available for just 3 dogs, confirming T-cell origin in 2 patients 
and B-cell origin in one dog. Five dogs were treated with combination antineoplastic chemotherapy 
either after the initial therapeutic pericardiocentesis alone or after pericardiocentesis followed by 
partial pericardiectomy6, but median survival times (MST) were short (157 days). One of the 5 dogs 
also received adjunctive radiation therapy. Seven dogs did not receive any treatment.  
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Aortic body tumours (chemodectoma/paraganglioma)  
Aortic body tumours can potentially arise from any anatomical site, although chemodectomas seem 
to be the most common type, occurring in the wall of the ascending aorta at the level of the heart 
base. Chemodectomas are non-functional tumours of paraganglial cells and therefore believed to be 
essentially benign with low metastatic potential (Fig. 1 A-B, Fig. 2 A). Conversely, paragangliomas 
arise from paraganglial cells located within the atria along the root of the great vessels and derive 
from the visceral autonomic ganglia.56 Extra-adrenal paragangliomas that are functional and secrete 
catecholamines are usually chromaffin positive and have been termed chromaffin paragangliomas 
or non-adrenal pheochromocytomas.38, 57 The current veterinary literature on this type of neoplasm 
is limited to case reports.38, 58, 59 A paraganglioma in an intracardiac location was identified at 
necropsy in the right atrium of a GSD which presented with signs of depression and anorexia.59 
Successful surgical excision of a left atrial paraganglioma is described, resulting in a survival time 
(ST) of 2 years with no adjuvant treatment.58 A functional chromaffin paraganglioma in the right 
atrium was reported in a 5 year old Labrador that presented with ascites secondary to caudal vena 
cava obstruction38: biopsies obtained through a left jugular venotomy were consistent with a 
neuroendocrine tumour, most likely chemodectoma. However, due to the dog’s clinical signs at the 
time of biopsies (transient hypertension and atrial fibrillation), a functional paraganglioma was 
suspected. This dog was euthanased hence no further outcome information was available, but 
electron microscopy showed numerous neurosecretory granules within the cytoplasm of the 
neoplastic cells, hence supporting the suspicion of a functional tumour. A similar report59 has 
described a case of a functional paraganglioma which stained positive for chromogranin indicating 
a neuroendocrine origin.  Intracardiac metastases of an aortic body tumour have also been described 
in one dog60, but metastases from these lesions seem uncommon. 
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Rhabdomyoma and rhabdomyosarcoma 
The exact histogenesis of rhabdomyoma is uncertain61, and whether cardiac rhabdomyoma is a true 
neoplasm or a hamartoma is still a controversial issue in the medical literature. In humans, cardiac 
rhabdomyomas are reported to regress spontaneously.62 Interestingly, a cardiac rhabdomyoma has 
been reported in a young Beagle (9 months-old)63, in which no signs of cardiac compromise were 
found; in this case the tumour was an incidental finding on necropsy and stained positive for PAS 
and desmin. The same tumour type has been reported in an older dog (6 years-old), associated with 
chylothorax.29  
Malignant muscle tumours are also described. A rhabdomyosarcoma was described in a GSD 
involving the right atrium and the right ventricle, causing right-sided heart failure (pleural, 
pericardial and abdominal effusions).64 The dog was euthanased after the mass was found on 
echocardiography and diagnosis confirmed at the time of necropsy. Another rhabdomyosarcoma 
was diagnosed in a Labrador Retriever with pericardial effusion,65 on biopsies obtained by 
thoracotomy65. One case report in a Great Dane with a primary cardiac rhabdomyosarcoma, 
demonstrated involvement of the heart, lungs, diaphragm, liver, kidney and greater omentum66, 
confirming that this tumour type has the potential to metastasise.  
 
Clinical signs 
Cardiac tumours can cause mild to severe, life-threatening clinical signs, or just be an incidental 
finding.8 The clinical signs caused by cardiac tumours are independent of the histological type8 and 
may be related to altered cardiovascular function caused by the mass effect or, more commonly, 
local haemorrhage/effusion into the pericardial space. Cardiac or pericardial tumours are 
responsible for most of the pericardial effusions documented in dogs (up to 60%)67, with HSA 
being the most common cause, followed by mesothelioma and aortic body tumours.67 Clinical signs 
associated with pericardial effusion secondary to cardiac neoplasia are not specific, but similar to 
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those caused by idiopathic pericardial effusion. Pericardial effusion can result in right atrial or even 
right ventricular tamponade and therefore cause decreased pre-load and compromised cardiac 
output and/or right-sided congestive heart failure.68 60, 61 Clinical signs may include acute collapse, 
exercise intolerance or lethargy and on physical examination there may be muffled heart sounds, 
tachycardia, pulse deficits, pale mucous membranes, weak femoral pulses, ascites, 
tachypnoea/dyspnoea or increased abdominal effort, subcutaneous oedema, jugular venous 
distension, jugular pulsations, positive hepatojugular reflux, weight loss and even vomiting.69, 70 
Dogs can also present with chylous effusions, either in the pleural9 or pericardial space.29  
Cranial vena cava syndrome can be observed in cases of heart base masses compressing the cranial 
vena cava. Syncopal episodes can also occur in cases of right ventricular outflow tract obstruction.71 
Occasionally, signs of left sided congestive heart failure can be present due to the location of the 
tumour, which can obstruct left ventricular inflow.3, 20 Sudden death is also reported, most likely 
related to rupture of the tumour with haemorrhage and/or cardiac tamponade, but also potentially 
secondary to arrhythmias.3 Tachyarrhythmias (mainly ventricular arrhythmias either due to the 
primary cardiac mass or associated with splenic/hepatic masses) or bradyarrhythmias (e.g. 3rd 
degree atrio-ventricular block [AVB]31, 72) have been described.  
Aupperle et al. reported that in dogs with metastatic cardiac tumours, the clinical presentation and 
symptoms correlated mainly with the primary extra-cardiac tumour: cardiac metastases were not 
suspected ante-mortem in any case.50 
 
Diagnosis 
History and physical examination may help in the diagnostic process, although cardiac tumours 
may produce no overt abnormalities on routine clinical examination, unless associated with 
pericardial effusion (as detailed above).  
Cardiac masses can be difficult to detect and even after detection, obtaining a definitive diagnosis 
may be challenging. In the clinical setting, masses from extra-cardiac locations are routinely 
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sampled to achieve a cytological or histological diagnosis or as part of the staging of an oncologic 
condition. Whenever feasible, cardiac masses may also be aspirated as this will provide more 
prognostic information and allow specific treatment (Fig. 3). Sampling of cardiac masses is not a 
routine procedure, mainly given the potential risk of arrhythmias and haemorrhage. However, in the 
authors’ experience, this procedure is relatively safe and fine needle aspirates seem to have a 
reasonable diagnostic accuracy (unpublished data; manuscript under review). Transvenous 
endomyocardial biopsies73, 74 and open chest or thoracoscopic biopsies74, 75 can also be performed in 
selected patients and can provide a histopathological diagnosis (Fig. 4). 
 
An electrocardiogram may be used as a diagnostic tool. Cardiac tumours can cause pericardial 
effusions and be associated with low voltage QRS and electrical alternans. In addition, conduction 
disturbances76 or arrhythmias (either tachy- or bradyarrhythmias) can also be detected.31, 72 
However, these findings are not specific for the presence of a cardiac neoplasm.  
 
When pericardial effusion is present, cytology should be performed to try to distinguish benign 
from malignant pericardial effusions, or identify what type of cardiac neoplasia is present. A study 
evaluating the diagnostic utility of pericardial fluid analysis reported frequent false positive (13%) 
and false negative (74%) results.77 Its utility is variable depending on the tumour type, and there is 
an improved diagnostic yield from effusions with a PCV of less than 10%.78 MacGregor et al 
diagnosed cardiac lymphoma in 7/12 cases by means of pericardial fluid analysis6, possibly because 
samples of lymphoid tumours are usually associated with a higher cellularity and more likely to be 
exfoliative and less haemorrhagic. The pH of the pericardial effusion has also been evaluated79 as a 
mean to distinguish between idiopathic or neoplastic effusion, however due to a significant overlap 
between the two groups, this is not currently recommended as a diagnostic test.80 
The utility of serum concentrations of Troponin I and Troponin T to diagnose cardiac neoplasia and 
to differentiate benign from malignant pericardial effusions has been investigated. Serum troponin I 
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was shown to be higher in dogs with cardiac HSA than in dogs with extra-cardiac HSA, dogs with 
extra-cardiac neoplasia other than HSA and dogs with pericardial effusion not caused by HSA.81, 82 
In cases of pericardial effusion, Troponin I increases not only in the plasma but also in the 
pericardial fluid, but the concentration of Troponin I in the effusion does not appear to help 
differentiating between aetiologies.83 Troponin T was not significantly different between dogs with 
idiopathic pericardial effusion and dogs with pericardial effusion caused by a cardiac HSA.82  
 
Thoracic radiographs can raise the suspicion for cardiac tumours or pericardial effusion, if there is a 
visible change in the cardiac silhouette. For staging purposes, lung metastases can also be 
identified.8 
 
Echocardiography has been shown to have a high specificity (100%) and sensitivity (82%) for the 
detection and characterisation of masses in dogs with pericardial effusion.84 The location and size of 
the tumour may help predict the diagnosis84 (for example HSA appears to be more common in the 
right atrium/right atrial appendage), but a presumptive diagnosis based on the anatomical location is 
only moderately accurate84, 85, with an accuracy ranging from 50% to 78% depending on the tumour 
type (Fig. 1). In addition, reports of valvular primary or secondary tumours44-46 highlight the fact 
that such lesions have been misdiagnosed as endocarditis by less experienced ultrasonographers, 
and therefore a neoplastic process should be considered as a differential diagnosis in some cases of 
valvular abnormalities. 
 
Advanced imaging modalities such as computed tomography (CT), positron emission tomography 
(PET) scans (Fig. 5) and magnetic resonance imaging (MRI) are useful diagnostic tools for 
detection of cardiac tumours.67, 86-88 Pneumopericardiography47, angiography71 and gated 
radionuclide imaging58 are also reported. Multidetector CT was not superior to echocardiography in 
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detecting cardiac masses in dogs with pericardial effusions despite its benefits in the identification 
of pulmonary metastases.89  
Cardiac MRI was used to differentiate neoplastic from non-neoplastic pericardial effusions, but this 
modality did not improve the accuracy of a final diagnosis of cardiac tumours when compared to 
echocardiography.90  
 
Treatment and prognosis 
Multiple treatment options exist for cardiac tumours including surgery, chemotherapy and 
radiotherapy (RT), in addition to symptomatic treatment, which may be necessary to stabilise 
patients that present with cardiac tamponade (e.g. pericardiocentesis). Adequate control of the 
primary tumour is often difficult to achieve and this limits survival, particularly in cases with severe 
clinical signs. The lack of a definitive diagnosis in most cases may also mean that some patients do 
not receive the most appropriate treatment: this is most relevant if a chemosensitive tumour (e.g. 
lymphoma) is not diagnosed.  
Without treatment, the prognosis for cardiac tumours is variable but generally poor. A study of 51 
dogs diagnosed with histologically-confirmed HSA reported median survival times (MST) of 7.1 
days (range, 1 to 26 days) for dogs that received no treatment.91 Pericardiocentesis as palliative 
monotherapy is also associated with a poor outcome.68, 84, 92-94 
 
Surgery  
Pericardiectomy for dogs with cardiac tumour associated pericardial disease conveyed a MST of 52 
days in 9 dogs92 compared to pericardiectomy for non-neoplastic pericardial disease (MST 792 days 
in13 dogs).92 While this study only included a small number of dogs’ cases with confirmed cardiac 
neoplasia, it suggests that pericardiectomy is advantageous over just pericardiocentesis, given 
recurrence of clinical signs associated with pericardial effusion is one of the main causes of 
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death/euthanasia. Pericardiectomy does increase the potential risk of severe and acute haemorrhage 
into the pleural space (instead of a contained haemorrhage into the pericardial space), but overall 
appears to confer a survival advantage. Pericardiectomy and tumour resection resulted in a MST of 
86 days (range 10-202 days) in a group of 12 dogs91; in this case ST was found to be significantly 
longer when compared to dogs that received no treatment (8) or medical management alone (26). 
However, in another study on 143 dogs68, MST and recurrence of pericardial effusion did not seem 
to be affected by pericardiectomy in dogs with cardiac HSA. However, these results have to be 
interpreted with caution, as the tumour diagnosis was only presumptive in the majority of cases 
included in that study.  
Surgical excision is the treatment of choice for HSA, and is desirable as long as anatomic location 
permits (Fig. 6). There are a number of case series reporting successful surgery of cardiac tumours, 
though morbidity and mortality are high.  
In a study on 51 dogs using traditional thoracotomy for HSA resection,91 MST was 86 days (range, 
10 to 202 days) for dogs that had pericardiectomy and surgical resection of the HSA only and 189 
days (range, 118 to 241 days) for dogs that had surgical excision of the HSA and adjuvant 
chemotherapy. This compares favourably to palliative pericardiocentesis with no additional 
treatment (MST 7.1 days, range 1 to 26 days) or with non-chemotherapeutic medical management 
only (MST 27 days, range 1 to 188 days91). However, another study of 23 dogs94 reports shorter 
MST post surgery: MST was 42 days (range 0 to 138 days) for dogs treated with surgery alone, and 
175 days (range 36 to 229 days) for the dogs treated with surgery and chemotherapy. In this study, 
pericardiectomy was also performed in 21 (91%) dogs, while the pericardium was closed in 2 (9%) 
dogs. The 2 dogs in that study in which the pericardium was closed did not receive chemotherapy 
and lived 23 and 138 days after surgery. In both studies, ST was significantly longer for dogs that 
received adjuvant chemotherapy after surgery compared to those who received surgery alone, 
however the role of adjuvant chemotherapy cannot be further clarified due to the retrospective 
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nature (and potential bias in advising treatment and timing of euthanasia due to owners’ decisions) 
of the study. 
Thoracoscopic resection has been described in nine cases.95 Eight HSA and 1 pyogranulomatous 
lesion were resected, mainly from the right atrial appendage (8 dogs). One dog with a mass located 
at the base of the right auricle died during surgery, but no other postoperative complications were 
noted in the remainder of the patients. However, masses close to the base of the right atrial 
appendage may not be amenable to resection with thoracoscopy. Another report describes 
successful removal of a high right atrial HSA via subtotal thoracoscopic pericardiectomy96, 
achieving a ST of 177 days in combination with chemotherapy.   
There is a single case report describing a pericardial patch graft to repair the defect after resection 
of a right atrial HSA97; this dog also received adjunctive carboplatin and recurrence was 
documented 7 months later. A palliative RT protocol was started at that point and ST was 260 days 
after diagnosis.  
Aortic body and heart base masses that are not locally invasive may be more amenable to surgery. 
Malignant heart base masses tend to invade local vessels or lymphatics48, making resection difficult. 
For aortic body tumours69, 70, the recommended treatment includes pericardiectomy in order to 
better control clinical signs (e.g. pericardial effusion). In one case series of 25 heart base masses70, 
mean ST for dogs that underwent pericardiectomy (661 ± 170 days) was significantly longer than 
mean ST for dogs that were treated medically (pericardiocentesis, diuretics or chemotherapy), 
achieving a survival of 129 ± 51 days. There was no final diagnosis for any of the dogs in this 
study.  
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Chemotherapy  
Surgical excision of HSA is the treatment of choice, but when this is not feasible, chemotherapy 
options include cyclophosphamide-based chemotherapy, single agent anthracyclines, or 
anthracycline-based combination therapy, but data are limited and limited efficacy is expected in a 
gross disease setting. Conventional chemotherapy is most effective in the minimal residual disease 
setting, and for splenic HSA is used as post-operative adjunctive therapy to try to delay 
development of clinically significant metastatic disease. A doxorubicin-based combination protocol 
(VAC protocol98) for HSA has been shown to result in a MST of 172 days although no control 
group was included in the study and historical controls were used for comparison. Three dogs had 
concurrent right atrial as well as splenic involvement in this study, and this protocol has not been 
specifically evaluated for dogs with confirmed primary cardiac HSA.  
In cardiac HSA, chemotherapy may offer a survival advantage when compared to pericardiocentesis 
alone, but without the ability to achieve a compartmental excision of the primary tumour, as is 
achieved by splenectomy, the impact on survival will likely be less than as an adjunct in splenic 
HSA.  
In 23 dogs with cardiac HSA treated surgically94 by means of pericardiectomy and mass resection, 
mean ST after surgery without chemotherapy ranged between 43-46 days, whereas mean ST was 
164 days for dogs that also received adjuvant chemotherapy. Only eight of the 23 dogs received 
chemotherapy and protocols were doxorubicin alone in three dogs (ST 12, 36 and 188 days), 
doxorubicin and cyclophosphamide in three dogs (ST 118, 162 and 228 days) and doxorubicin, 
cyclophosphamide, and vincristine in one dog (ST 205 days). The chemotherapy protocol for the 
remaining dog was not specified. Time to initiation of treatment, cycles received and stage also 
varied between groups (with 7 [28%] dogs with documented metastatic disease at presentation).  
Thus the study lacks the power to demonstrate any difference between protocols. An individual case 
report in a dog receiving single agent doxorubicin after surgery reports similar survival time (177 
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days)96.  
Doxorubicin was also used in a study99 on presumptive cardiac HSA identified by 
echocardiography in 16 dogs, treated with chemotherapy alone. Histopathological diagnosis was 
performed after post-mortem examination in only 1 case, confirming HSA. These authors used 
doxorubicin either alone or in combination in a multi-agent protocol as already described in 
previous studies98 and achieved a MST of 139 days.  
A recent larger study100 compared the outcome of 64 dogs with a presumptive diagnosis of cardiac 
HSA on echocardiography, treated with doxorubicin as a first line treatment, versus 76 untreated 
patients. Although median progression-free survival (PFS) and MST were of short duration (66 and 
119 days respectively) in those dogs receiving chemotherapy, the authors found an improved 
survival when compared to the untreated group, whose MST was 12 days only. None of the dogs 
received pericardiocentesis or surgery before receiving chemotherapy, with the responders 
experiencing either complete response (CR) or stable disease (SD). Following the completion of the 
doxorubicin-based protocol, 1 dog was treated with vincristine and cyclophosphamide, whereas 20 
dogs that showed no response to doxorubicin received rescue chemotherapies (including vincristine, 
cyclophosphamide and carboplatin). Eleven dogs within the responders’ group also received 
metronomic cyclophosphamide, but this did not seem to affect the outcome significantly. 
Interestingly, metastatic disease at diagnosis was detected more frequently in the group receiving 
chemotherapy and this may have biased the clinician’s advice and subsequently the owners’ 
decision of pursuing further treatment. This study again lacks a histopathological confirmation of 
HSA but reflects a common situation encountered in clinical practice, where dogs are treated based 
on a presumptive diagnosis. Although suffering the limitations of a retrospective study, the results 
suggest a potential advantage in using chemotherapy alone in such cases.   
Cyclophosphamide-based metronomic chemotherapy has been used as post-operative adjunctive 
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treatment in splenic HSA101, showing a similar efficacy when compared to anthracycline-based 
protocols. Potentially cardiac HSA may be sensitive to the same type of treatment, but again the 
gross disease setting is not comparable. The authors have treated 2 dogs with cytologically 
confirmed atrial HSA with a cyclophosphamide-based metronomic protocol, achieving survivals of 
20 and 66 days, respectively, with both dogs being euthanased because of recurrence of clinical 
signs associated with pericardial effusion (unpublished data).    
Chemotherapy is the treatment of choice for cardiac lymphoma, as is recommended for other 
anatomic locations of lymphoma. A small study6 on 12 dogs showed that the MST of 5 dogs that 
received combination chemotherapy (including prednisone, vincristine, cyclophosphamide, L-
asparaginase, doxorubicin, mechlorethamine, procarbazine, lomustine) was 157 days. Of the 7 dogs 
that did not receive any treatment, MST for 6/7 dogs was only 15 days6. In this study, one dog 
treated with pericardiocentesis only survived > 1,169 days, making the original diagnosis 
questionable. This study also suggested that the prognosis for cardiac lymphoma was not as poor as 
for other stage V, substage b lymphomas.6 This was a very small study, and may also be influenced 
by clinician/owner bias in advising/declining any further treatment, hence dogs with a worse 
clinical presentation or more aggressive clinical signs may not have been treated and had a shorter 
survival.  
Future prospective studies may include new targeted therapies such as tyrosine-kinase inhibitors 
(TKIs), which may have a rationale if used as antiangiogenetic agents, especially in HSA cases102.  
For all medical therapies, complete remission is unlikely. Whatever the diagnosis, treatment may 
also require symptomatic management aimed at controlling tumour bleeding and potential 
arrhythmias, and other signs caused by the mass effect. Unlike other solid tumours, achieving 
partial remission (PR) or SD may not lead to adequate control of the associated clinical signs to 
enhance survival. 
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Radiotherapy  
A single case report103 described the use of conformational radiation therapy in a dog with 
chemodectoma; this resulted in a partial response (more than 50% reduction in tumour volume). 
The dog was symptom-free for 32 months, followed by additional 42 months subsequent to 
additional radiotherapy and pericardiectomy. Radiotherapy remains an interesting treatment option 
to treat heart base masses that are not easily accessible surgically, but more studies are needed to 
confirm the efficacy of this, and intensity modulated radiotherapy or other highly conformational 
techniques may be most appropriate. 
 
Cardiac tumours in cats 
Cardiac tumours are much less common in cats than in dogs, and tend to be malignant.7 One of the 
largest retrospective studies7 reporting 30 cardiac tumours found lymphoma to be the most 
common.  Thirteen cats, 4 of which were FeLV positive, had malignant lymphoma (12 B and 1 T 
cell). Metastases of extracardiac tumours occurred in the heart in 5 cases. As in dogs, cardiac 
metastases were predominantly located in the interventricular septum and the left ventricular wall.7 
Cardiac metastases of a solid adenocarcinoma of the lungs and of mammary adenocarcinomas have 
also been reported in the same study. A case of a primary pericardial HSA in a 13 year-old domestic 
shorthair cat with metastases to the liver has also been described104.   
 
Recently pericardial lymphoma has been reported in 7 cats105 (1 non-classified, 3 T-cell and 3 B-
cell). Diagnosis was confirmed by cytology with fine needle aspirates of the pericardium and 
cytology of the pericardial and pleural effusions. Clinical findings at presentation may include poor 
body condition, dehydration and dyspnoea. In most cases, there was echocardiographic evidence of 
diffuse thickening of the pericardium. Survival time ranged between 7–11 days when untreated or 
receiving single agent drugs (doxorubicin or prednisolone alone), except for one cat that received a 
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multi-drug chemotherapy protocol (CHOP protocol) and was still alive 750 days after diagnosis. 
The long survival time in this case was associated with complete remission confirmed on thoracic 
radiographs and echocardiography, but the real efficacy of chemotherapy in these cases warrants 
further investigations.  
Achieving stable disease, as in dogs, may not be beneficial for those tumours causing life-
threatening clinical signs.   
 
 
Conclusions  
Cardiac tumours are rare in dogs and cats and can be challenging to detect. Frequently, a cardiac 
mass can be identified by echocardiography, however a definitive diagnosis is usually only acquired 
post-mortem. Sampling of accessible cardiac masses should be considered as this may influence 
prognosis and treatment, as well as outcome.  
Most of the studies reported here are retrospective in nature, limiting the information that can be 
inferred. A significant sample selection bias has to be suspected, both on the side of veterinarians 
making treatment recommendations and dog owners. Retrospective studies generally require large 
sample sizes, in order to yield meaningful results, and many of the studies are on small numbers of 
cases. Cardiac neoplasms are uncommon in veterinary medicine, and prospective studies are 
therefore likely to be limited by the slow accrual of cases unless these are very large multicentre 
studies.  
Treatment options are limited, but in cases of HSA best outcomes are achieved with a combination 
of surgery and chemotherapy (most commonly anthracycline-based). Cardiac lymphoma may 
respond to multi-agent chemotherapy protocols. However, whatever the diagnosis, treatment often 
requires symptomatic management of tumour bleeding and potential arrhythmias other than signs 
caused by the mass effect, as achieving complete remission is uncommon. Unlike other solid 
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tumours, achieving PR or SD may not lead to adequate control of the associated clinical signs to 
enhance survival. RT is an interesting but not readily accessible option for heart base tumours. 
Medical management, beyond adjunctive chemotherapy in HSA, requires further investigation but 
combination chemotherapy is recommended for lymphoma.  
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Figure 1: Echocardiographic appearance of cardiac masses. A: right parasternal long axis four chamber 
view, modified to optimise the large and rounded heart base mass located dorsal to the left atrium and right 
atrium. Cytology of fine needle aspirates of this mass revealed chemodectoma. B: right parasternal short axis 
view at the level of the heart base, modified to optimise the small and rounded heart base mass. Most likely 
differential diagnosis: chemodectoma. C: left apical view of the right atrium and right ventricle showing a 
mass arising from the right atrium and extending into the right atrio-ventricular groove. Cytology of fine 
needle aspirates of this mass revealed haemangiosarcoma. D: right parasternal long axis view showing a 
small and mildly heterogeneous mass in the base of the interventricular septum. Cytology of fine needle 
aspirates of this mass revealed haemangiosarcoma.  	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Figure 2. (A) Post-mortem appearance of a chemodectoma at the level of the heart base and surrounding the 
aorta. (B) Post-mortem appearance of a diffuse haemangiosarcoma. Both tumour types have been confirmed 
on histopathology.  	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Figure 3: Cytological features of cardiac tumours obtained by fine needle aspiration. Diff-quick stain. A, B: 
chemodectoma. Note the naked nuclei suggesting a neuroendocrine origin. Marked anysokariosis is also 
visible (magnification, 100 x). C, D: Haemangiosarcoma. Numerous mesenchymal cells on a background of 
erythrocytes are visible in figure C (magnification, 20 x). A detail of the mesenchymal cells with basophilic 
and vacuolated cytoplasm is shown in figure C (magnification, 100 x).  	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Figure 4: Histopathological features of cardiac tumours. A: Haemangiosarcoma. Spindle to polygonal cells 
with indistinct cytoplasmic limits arranged in interlacing bundles enclosing blood-filled spaces. (H&E, 
original magnification 400x) B: Chemodectoma. Tumour polygonal cells are arranged in nests and packets 
supported by a fine and delicate fibrovascular stroma (H&E, original magnification 100x). 	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Figure 5: CT appearance of a chemodectoma. Oblique (A) and transverse (B) post-contrast thoracic CT at 
the level of the aortic root. There is a large, well marginated, irregularly shaped, heterogeneous and 
hypoattenuating mass dorsal to the aortic root, displacing the heart ventrally. The image B shows the mass in 
the plane of the aortic root. Note the ventral and left-sided displacement of the aorta. R: right, L: left; Ao: 
aorta; C: cardiac silhouette; T: trachea; M: mass. 
 
 
 
 
 
 
 
 
 
Figure 6. (A) Intraoperative view of a right atrial haemangiosarcoma (HSA). (B) Right auricular appendage 
HSA before surgical excision.  
 
 	  
